United States Patent 7,018,992: Scope, Claim Map, and US Landscape
What does US 7,018,992 claim?
US 7,018,992 is directed to a vaginal estradiol therapy for atrophic vaginitis using low-dose estradiol tablets with low systemic absorption and, in some dependent claims, explicit formulation and treatment regimen parameters.
Core independent structure (Claim 1):
- Indication: “treating atrophic vaginitis”
- Route: vaginal administration
- Dose: “about 10 μg estradiol”
- Frequency: “once or twice per week”
- Dosage form: “tablet form”
Key dependent claim themes:
- Patient population: menopausal or post-menopausal women (Claim 2)
- Lower-dose alternative: about 5 μg estradiol at twice weekly (Claim 3)
- No progestogen: absence of progestogen co-administration (Claim 4)
- Treatment duration: courses extending beyond 2 weeks, beyond 1 month, and beyond 3 months (Claims 5-7)
- Specific tablet composition (Claim 8)
- Film coating composition (Claim 9)
- Pharmacokinetic target: “undetectable systemic absorption” (Claim 10)
- Pharmacodynamic target: vaginal pH “below about 5.5” (Claim 11)
- Outcome metrics: symptom relief, urogenital atrophy improvement, pH reduction, and cytologic maturation (Claim 12)
How broad is the independent claim (Claim 1)?
Claim 1 is broad on several fronts and narrow on others.
Breadth drivers (what Claim 1 covers broadly)
- Route is fixed to vaginal administration.
- Dosage form is fixed to tablet.
- Dose is limited to “about 10 μg.”
- Frequency allows a range: once or twice per week.
- Indication fixes the clinical target: atrophic vaginitis.
- The claim does not require:
- a particular exact excipient profile,
- a particular coating recipe,
- a specific measured pharmacokinetic endpoint (that appears in Claim 10),
- a specific vaginal pH endpoint (that appears in Claim 11),
- “no progestogen” (that appears in Claim 4),
- duration thresholds beyond “treatment” generally (that appears in Claims 5-7).
Narrowing features (what materially constrains Claim 1)
Claim 1 is constrained by the combination of:
- low dose (about 10 μg) and
- tablet delivery and
- vaginitis indication and
- weekly dosing cadence (once or twice per week).
Those elements jointly limit the claim’s reach against products that are:
- higher dose (even modestly above “about 10 μg” if outside “about” tolerance in practice),
- non-tablet vaginal forms (cream, ring, pessary, gel),
- more frequent dosing schedules (daily regimens),
- estradiol delivered to achieve systemic estrogen levels rather than local therapy, if the claim interpretation ties to “atrophic vaginitis” low-dose local treatment context.
What do the dependent claims add in scope?
Dependent claims expand or refine Claim 1 in ways that create practical “design-around” and “proving-infringement” pressure points.
Dose and dosing schedule forks
- Claim 3: “about 5 μg estradiol” twice weekly in tablet form.
- This is a second dosing pillar that reduces the chance that competitors can avoid by moving from 10 μg to 5 μg if they dose at twice weekly.
- Claims 5-7: extend weekly administration across defined duration thresholds.
- More than 2 weeks (Claim 5)
- More than 1 month (Claim 6)
- More than 3 months (Claim 7)
In practice, these duration thresholds matter most for:
- clinical trial protocols,
- product labels that specify treatment duration,
- any commercialization plan that uses fixed course durations.
Concomitant therapy constraint
- Claim 4: no progestogen administered.
- This limits infringement if a competitor’s regimen includes progestogen. It is also relevant to how prescribers manage uterine status and labeling language around endometrial protection.
- If a competitor’s product is marketed with a co-therapy requirement or prescriber guidance that progestogen is used, it can move practice away from Claim 4. If marketed without progestogen and used accordingly, Claim 4 stays available.
Formulation-specific claims (strong leverage for “literal” infringement)
- Claim 8 recites specific tablet excipients and amounts:
- about 53.7 mg hypromellose
- about 17.9 mg lactose monohydrate
- about 8 mg maize starch
- about 0.4 mg magnesium stearate
- Claim 9 specifies film coating composition:
- about 0.5 mg hypromellose
- about 0.06 mg macrogel 6000 (PEG 6000 NF)
These two claims are critical because they create:
- a direct path to literal infringement for products with matching excipient and coating recipes, and
- a clearer design-around route via formulation changes, assuming dose and tablet form remain within the independent claim boundaries.
Pharmacokinetic and pharmacodynamic endpoint claims
- Claim 10: “undetectable systemic absorption” following administration.
- Claim 11: vaginal pH “below about 5.5.”
- Claim 12: clinical and cytologic outcomes (relief of symptoms, improved urogenital atrophy, decreased pH, improved cytologic maturation).
These endpoint claims are especially relevant because competitors may argue non-infringement if:
- systemic estradiol exposure is detectable by the competitor’s assay and/or dosing results in measurable systemic levels (even if still “low”).
- vaginal pH reductions do not meet “below about 5.5.”
- trial endpoints and measurement thresholds do not match the described “results.”
In infringement analysis, endpoint claims create an evidentiary requirement: the accused product’s administration must produce the recited outcomes in the context of the claim.
Claim-by-claim scope map (what has to be true)
| Claim |
What must be done / achieved |
Scope impact |
| 1 |
Vaginally administer ~10 μg estradiol tablet; once or twice per week; treat atrophic vaginitis |
Main gatekeeper; broad on formulation and outcomes |
| 2 |
Patient is menopausal/post-menopausal |
Narrows patient class |
| 3 |
Vaginally administer ~5 μg estradiol tablet twice weekly |
Captures alternative low-dose regimen |
| 4 |
No progestogen administered |
Narrows regimen to estrogen-only local therapy |
| 5 |
Administration continues >2 weeks |
Duration threshold |
| 6 |
Administration continues >1 month |
Duration threshold |
| 7 |
Administration continues >3 months |
Duration threshold |
| 8 |
Tablet contains specified excipient amounts |
Literal formulation hook |
| 9 |
Tablet coated with specified film composition |
Literal formulation hook |
| 10 |
Undetectable systemic absorption |
PK endpoint hook |
| 11 |
Vaginal pH <~5.5 |
PD endpoint hook |
| 12 |
Outcomes include symptom relief, urogenital atrophy improvement, pH decrease, cytologic maturation |
Outcome hook |
What is the likely “patent landscape” around this claim set?
Based strictly on the claim language, US 7,018,992 sits at the intersection of:
- low-dose vaginal estradiol tablets (local therapy),
- low systemic absorption positioning,
- weekly dosing schedules (not daily),
- and potentially a particular tablet excipient/coating recipe.
In a typical US landscape for vaginal estradiol therapies, competitive coverage clusters around:
1) Formulation patents (specific excipients, dissolution profile, film coating).
2) Dosing-regimen patents (weekly or twice-weekly schedules; treatment duration).
3) Use patents (indication: atrophic vaginitis, GSM-related symptom control).
4) Pharmacokinetic/pharmacodynamic characterization patents (undetectable systemic estradiol; vaginal pH improvement; cytologic maturation).
US 7,018,992 itself contains all four buckets within the claim set:
- regimen (Claims 1, 3, 5-7),
- use (Claim 1, 2),
- formulation (Claims 8-9),
- PK/PD/outcomes (Claims 10-12).
Practical competitive stress points created by this patent
A competitor attempting to enter or expand in US vaginal estradiol for atrophic vaginitis with a tablet product faces four main “hit tests”:
1) Dose and schedule
- 10 μg once-or-twice weekly and/or 5 μg twice weekly.
2) Dosage form
- must be a tablet for infringement of Claims 1 and 3.
3) Regimen context
- no progestogen for Claim 4.
4) Evidence of endpoint attainment
- “undetectable systemic absorption” and vaginal pH “below about 5.5” for Claims 10-11.
Design-around map (what likely breaks infringement)
From a claims-only standpoint, the most direct ways to reduce risk are:
- Change dosage form away from tablet (cream, ring, gel, pessary).
- Use a non-claimed estradiol dose/schedule combination (avoid “about 10 μg once or twice weekly” and “about 5 μg twice weekly” in practice).
- Include progestogen in the regimen (target Claim 4).
- Alter tablet excipient recipe and film coat composition (target Claims 8-9).
- Avoid meeting endpoint thresholds (target Claim 10-11), though this is less controllable because endpoints can depend on drug action, not just manufacturing.
Scope tension: tablet-form estradiol use vs systemic estradiol monitoring
The claim set creates dual compliance targets:
- a local therapeutic dose and schedule, plus
- proof of “undetectable systemic absorption” and/or pH improvements.
If a competitor’s product results in detectable systemic absorption by the relevant assay conditions, it can argue against Claim 10 even if it still improves symptoms and pH. If it fails to push pH below about 5.5, it can argue against Claim 11 and possibly parts of Claim 12’s outcome subset.
Business implications: where infringement risk is highest
Without bringing in external document-specific facts beyond what you provided, the highest risk scenarios based on Claim 1 and its dependent hooks are:
- A vaginal estradiol tablet marketed for atrophic vaginitis with:
- dosing consistent with once-or-twice weekly 10 μg, or twice-weekly 5 μg,
- and without progestogen co-administration.
- A product whose tablet excipient composition and film coating match Claims 8-9.
- Clinical use that targets long courses beyond 1 to 3 months, and includes measurement or study data supporting systemic absorption and vaginal pH changes that satisfy Claims 10-12.
Key Takeaways
- US 7,018,992 is a vaginal tablet estradiol method patent for atrophic vaginitis centered on weekly low-dose regimens: ~10 μg once or twice weekly (Claim 1) and ~5 μg twice weekly (Claim 3).
- The claim set includes formulation specificity (tablet excipients and film coating: Claims 8-9), regimen constraints (no progestogen: Claim 4; duration thresholds: Claims 5-7), and endpoint hooks (undetectable systemic absorption: Claim 10; vaginal pH < about 5.5: Claim 11; outcomes: Claim 12).
- Design-around effort should prioritize: dose and schedule, tablet vs non-tablet route/form, progestogen use context, and (if pursuing literal infringement avoidance) matching excipient/coating changes.
- Evidence packages matter: endpoint claims depend on measured systemic estradiol detection, vaginal pH, and cytologic maturation/symptom outcomes.
FAQs
1) Does Claim 1 require a specific excipient composition?
No. Claim 1 only requires estradiol administered vaginally in tablet form at about 10 μg with once or twice weekly dosing for treating atrophic vaginitis. Specific excipients appear in Claim 8.
2) Is the patent limited to 10 μg estradiol only?
No. Claim 3 adds a second regimen: about 5 μg estradiol administered twice weekly in tablet form.
3) Can a product avoid infringement by using a different estradiol dose?
Risk decreases if the regimen does not fall within “about 10 μg once or twice per week” (Claim 1) or “about 5 μg twice weekly” (Claim 3). Endpoint and duration claims can still apply depending on practice.
4) What elements most strongly support literal infringement?
Tablet formulation details in Claims 8-9 and the endpoint conditions in Claims 10-11 (and the outcome bundle in Claim 12) provide the most “yes/no” style proof points when matched exactly.
5) How do progestogen-related claims affect real-world use?
Claim 4 requires no progestogen is administered. Regimens that include progestogen use (and are practiced accordingly) move away from Claim 4, even if other elements match.
References
[1] Provided claim text for US Patent 7,018,992 (user-supplied).
